400 Reasons to Not Miss Out

5 May

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Are you looking for early-stage investors? Digital RESI, June 7-9 is the (virtual) place to be! Don’t take my word for it, though. Check out the investors and strategic partners who are already registered for Digital RESI June and decide for yourself how you want to connect with 400+ top early-stage investors and strategics. You can book meaningful meetings with the right players on the powerful RESI Partnering Platform, and you still have a chance to compete in the Innovator’s Pitch Challenge. Be sure to register by this Friday, May 6 to save $200 on registration.

Confirmed Investors and Strategic Partners*

*As of May 4, 2022

CI05052022

Building the Perfect Pitch

5 May

By Karen Deyo, Director of Investor Research, Israel BD, LSN

A perfectly honed pitch is an important part of a startup’s bag of tricks. Many think that having a good pitch is easy because no one knows their company better than they do, and telling people about it is simple enough, right? Wrong! Building a concise pitch with the right amount of information to tell enough of the story to catch an investor’s attention can be a long and arduous process. When working with some of our branding and messaging clients, the elevator pitch can go through dozens of drafts before finding the right balance.

A good pitch should give investors a snapshot of your technology, your stage of development, what makes your technology unique, what you are looking to raise and what milestones you are looking to achieve. Some companies may also choose to highlight any relevant experience with the management team, the involvement of a KOL, or maybe a key partnership that they have developed. Each elevator pitch is unique, depending on the company and what part of their story is crucial to highlight. The one thing that all pitches have in common is that they take a lot of practice to perfect. However, you cannot practice in a vacuum – getting solid feedback is a critical part of developing a solid pitch.

This is where pitch sessions, like RESI’s Innovator’s Pitch Challenge (IPC) come in. The IPC provides a chance to hone your pitch, practice pitches in different lengths, from the 4-minute prerecorded pitch to the 1-minute live pitch during the Q&A session and get a glimpse of what questions an investor may ask for clarification. Participating in pitch sessions like the IPC gives you a glimpse into what questions investors are frequently asking you. This may indicate an area of your pitch that needs more work, or a part of your company strategy that you should develop more fully to appeal to more investors. Joining the IPC is a wonderful tool to help you make a great first impression.

Join Life Science Nation for a FREE Bootcamp in preparation for the Innovator’s Pitch Challenge.

Tuesday, May 10, 11AM EDT
Preparing to Pitch at RESI 
  • Greg Mannix, Vice President International Business Development, General Manager Europe, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.

The application deadline for the IPC has been extended, so it’s not too late to apply for the IPC for Digital RESI June – apply here!

The Voices of RESI

5 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

Panels are an integral part of the Redefining Early Stage Investments (RESI) conference series. They cover topics relevant to the fundraising entrepreneur, but they also feature prominent voices from both sides of the deal-making equation. RESI panels demystify the investment process by highlighting speakers from various investment firms representing different types of capital, including corporate venture, impact investors, endowments, foundations, private equity, family, offices, angels, incubators, and accelerators. RESI panels also shine a spotlight on entrepreneurs who have successfully raised funds and are willing to share their early-stage journeys, as well as best lessons learned along the way.

Check out the most recent list of speakers joining Digital RESI June who are participating virtually to shed light on the ever-changing landscape of early-stage life science and healthcare. Join them June 7-9 and save $200 on early bird rates by Friday, May 6.

Michael Baran
Executive Director, WRD and Principal
Pfizer Ventures
Kaitlin Christine
Founder & CEO
Gabbi
Marina Cortes
Venture Partner
SandBanks Capital
David Gordon
Head of Investments
Longliv Ventures
James Hardiman
Partner
Data Collective
Sarah Hippert
Program Manager
Techstars
Brenda Hogan
Chief Investment Officer
Ontario Capital Growth Corporation
Baudouin Hue
Partner
Karista
Ozan Isinak
President, Central Canada
Keiretsu Forum
Kristin King
Member
Boston Harbor Angels
Bill Kuziel
Analyst and Investor
MedPro Investors
Sebastien Latapie
Principal
Dynamk Capital
Seo Lee
Principal
SV Investment
Eric Levitan
Founder and CEO
Vivo
Ben Nahir
Venture Principal
Elevate Capital
Maria Luisa Pineda
Founder & CEO
Envisagenics
Gayathri Radhakrishnan
Senior Director Venture Capital – AI Fund
Micron Ventures
Katherine Relle
Vice President
Accelmed
Jane Rho
Investor
DaVita Venture Group
Surbhi Sarna
Group Partner
Y Combinator
Yaniv Sneor
Founding Member
Mid Atlantic Bio Angels
Eran Steinberg Imaging Arts Vangelis Vergetis
Co-Founder & Executive Director
Intelligencia.ai
Sa’ar Yaniv
Director of Business Development
Fortress Biotech
Derek Yuan
Senior Associate
LYFE Capital
Lu Zhang
Managing Partner
Fusion Fund
Alex Zhavoronkov
CEO
InSilico Medicine
  Cheryl Zimberlin
Investment Director
M Ventures
 

Hot Investor Mandate: Corporate VC Firm Invests Up to $10M in Diagnostics and Digital Health Companies Based in the USA or Those Interested in USA Markets

5 May

A corporate venture firm headquartered in USA invests $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused; however, the firm will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm is open to all types of management teams but have a preference for entrepreneurial experience, however the firm has also backed first time founders. For companies not in the diagnostics or device space, the firm likes to see at least $1M in ARR. They firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA and Europe-Based VC Firm Seeks Early-Stage Life Science Companies in All Sectors, With Strong Interests in Platform Technologies

5 May

A venture capital firm with USA and Europe offices is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm With RMB and USD Funds Invests Primarily in Therapeutics, Most Interested in CAR-T, Small Molecule Therapies, CRISPR, and More

5 May

A venture capital firm with offices in USA and China manages both RMB and USD funds. The firm’s USD fund has invested in 7 companies, half of which are in the novel drugs area, and will continue to invest in seed to pre-Series A. The typical allocation size is $0.5-1 MM, and will occasionally go up to $3.5 MM.

The firm is mainly interested in therapeutics innovations, including orphan drugs, from pre-clinical to Phase II. Of special interest are: CAR-T, small molecules and CRISPR technologies. The firm is also open to medical device companies, from development to clinical stage, but holds a strict valuation on diagnostics companies. The firm is less interested in digital health.

The firm has no specific company & management team requirements. Diversity in gender and race is greatly encouraged.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC & Growth Equity Firm Focuses on Seed to Series B Investments on Life Science Tools and Services Enabling Development of Life-Saving Therapies

5 May

A venture capital / growth equity firm located in New York City. The firm focuses on the Life Science Industrials and invests in companies that develop tools, technologies, and services for discovery, development, and manufacturing of biologics and related therapies. The firm is focused on early stage venture and growth equity investments. Typical equity investments range from $500k-$7 million. The firm has $65M AUM, 10 active portfolio companies to date, and is open to leading or co-leading in a financing round.

Within life sciences, the firm is specifically focused on life science industrials: the tools, technologies, and services that enable the discovery, development, and manufacturing of life-saving therapies. The firm does not invest in therapeutics or medical devices. The firm considers Seed to Series B stage opportunities.

The firm partners with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to working with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: